Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
about
Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor ModulatorsX-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11 -Substituted SteroidsSelective progesterone receptor modulators: an updateOvarian steroids, stem cells and uterine leiomyoma: therapeutic implications.Role of nuclear progesterone receptor isoforms in uterine pathophysiology.Delivery systems for hormone replacement therapy.Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs).Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.Histopathologic changes in the uterus, cervix and vagina of immature CD-1 mice exposed to low doses of perfluorooctanoic acid (PFOA) in a uterotrophic assay.Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo.Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids.Contraceptives with novel benefits.Novel actions of progesterone: what we know today and what will be the scenario in the future?Recent advances in structure of progestins and their binding to progesterone receptors.Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.Proteoglycans in Leiomyoma and Normal Myometrium: Abundance, Steroid Hormone Control, and Implications for Pathophysiology.Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780.BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies.Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma.The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression
P2860
Q27671815-F9C1821D-5B29-4B34-85C8-152C73099D29Q27678748-EB11EA16-B90B-4A56-B063-93AE317B7AC9Q28239255-9D73AF54-C73B-470E-8D4F-FD5D520CC5A0Q34437666-5477DA54-7159-4D45-9789-BA604BBFF869Q34448400-447D391B-57D2-4C69-9343-5B92E54633E6Q34498227-191F1A9D-597A-46CC-BF25-D4F7F33FB3D0Q34583316-31B8971A-6C32-47D9-8B46-F8C8C13928DCQ34674982-1DBA1939-A270-4CF0-89CD-027797678CD4Q35996126-8AFB8A4D-3989-47DA-BCF2-F7B7CFFFF69DQ36111250-00DBA207-432F-415B-871E-8A3BFB276E30Q36525065-342AA9FA-4095-41DD-8CA3-71675A069D01Q37035798-EBE8AA66-E438-4234-B0CA-516F3BBE15CCQ37315958-EEC32484-4C9E-4582-A835-C122FC097434Q37965736-8ADFB892-504A-4FBB-ABF6-3D0C9CC77393Q38024835-7EB6DD93-C97D-4D03-95FB-46BA8D414239Q38199191-362A07BE-CB9D-4ABD-9486-FFCFE619565BQ38569796-532956B7-4EB6-4E5C-AAC0-BAB968C0DC0AQ38603051-ED0AE61A-E81F-49C7-92FD-E00F005E30A7Q38831211-6A28AF5D-9F6E-4C1B-B3A0-2DFDDB1CF2C4Q40266830-A82A078E-9584-45D5-9D3D-ABFF4A8793C8Q45167319-700F1C4C-4DBA-42D2-A6F8-96F1E97C3FA7Q46167525-889F0B6D-A9AF-46DB-A1CA-234912335406Q50687024-9BDF72E2-F6EA-4A52-A3C2-064CADF9DB88Q55399257-34250915-B5E1-4725-8354-FD7033709EBDQ56741555-E571FEA2-BB9B-4799-B726-EDBAB62E93F4
P2860
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@ast
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@en
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@nl
type
label
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@ast
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@en
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@nl
prefLabel
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@ast
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@en
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@nl
P2093
P1433
P1476
Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy
@en
P2093
Birgitt Schneider
Deborah DeManno
Gerd Schubert
Holger Hess-Stumpp
Kristof Chwalisz
Ramesh Garg
Ronald Lee
Walter Elger
P304
P356
10.1016/J.STEROIDS.2003.09.008
P407
P577
2003-11-01T00:00:00Z